News

Congressman Chaka Fattah recently met with Amarantus, a biotechnology firm specializing in discovering and developing treatments and diagnostics for Alzheimer’s disease and other degenerative brain conditions, to discuss ongoing and future neurologic research strategies. Gerald Commissiong, the CEO of Amarantus, and Robert Farrell, the CFO, had briefed Congressman…

One of the biggest challenges that research and development in the field of Alzheimer’s Disease faces is not the discovery of new treatment candidates, but the lack of funding to advance these discoveries into human testing. In addition, very few funding sources address early-phase clinical drug trials and, as a…

A researcher from the University of Oklahoma is currently developing a new therapy to address Alzheimer’s disease by using biopharmaceutical proteases. The goal is to target the harmful amyloid beta plaque that builds up in the brains of AD patients. If successful, the scientist expects this approach to be cheaper, and…

Amarantus BioScience Holdings, Inc., a biotechnology company committed to developing diagnostics in neurology and to advance therapeutic products in several areas such as neurology, ophthalmology, psychiatry and regenerative medicine, recently announced the formation of an Alzheimer’s disease Diagnostics Scientific Advisory Board (SAB). The company also designated three renowned experts in Alzheimer’s disease and neurological disorders as its first members: Paula…

A recent study titled ”Individuals with Alzheimer’s disease exhibit a high prevalence of undiagnosed impaired glucose tolerance and type 2 diabetes mellitus,” conducted by Scott Turner MD, PhD from Georgetown University and colleagues, found that 43% of Alzheimer’s disease (AD) patients have undiagnosed impaired glucose intolerance. The findings…

A recent study published in the Journal of Alzheimer’s Disease titled “A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer’s Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks“ showed that women…

A research article, titled, “Blood-Brain Barrier Breakdown in the Aging Human Hippocampus” published in the journal Neuron by a team of investigators from the Zilkha Neurogenetic Institute (ZNI) at the University of Southern California (USC) Keck School of Medicine used high-resolution MRI analysis…

Pharnext, a biopharmaceutical company that develops therapeutics called pleodrugs that simultaneously target multiple key disease pathways for serious orphan and common neurological diseases, recently announced the pre-clinical findings of their ongoing Phase 2 clinical trial designed to examine the efficacy and safety profile of on of their pipeline pleodrugs, called…

AC Immune SA recently announced it has signed an exclusive worldwide license agreement and collaboration contract with Janssen Pharmaceuticals, Inc. to develop and commercialize anti-Tau vaccines to treat Alzheimer’s disease. According to the contract, Janssen Research & Development, an affiliate of Janssen Pharmaceuticals, Inc., will advance the development of the vaccine ACI-35 which is…

A team of researchers from Japan found that Alzheimer’s symptoms can be reduced when sugars are averted from binding to one of the disease key enzymes, named BACE1. The study entitled “An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer’s disease“, was published…